Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.
Hillstar Bio has raised $67.0M in total funding. The most recent round was Series A. The last funding was announced in March 2025.
Hillstar Bio's investors include Novo Holdings, Frazier Life Sciences, Hummingbird Bioscience, Droia Ventures, LifeArc Ventures.
Hillstar Bio is headquartered in Boston, United States.
Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.
Hillstar Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hillstar Bio — Funding & Investors." VCBacked, March 25, 2025, https://www.vcbacked.co/company/hillstar-bio. Accessed September 7, 2026.
VCBacked. (2025). Hillstar Bio — Funding & Investors. Retrieved September 7, 2026, from https://www.vcbacked.co/company/hillstar-bio
{{cite web |title=Hillstar Bio — Funding & Investors |url=https://www.vcbacked.co/company/hillstar-bio |website=VCBacked |access-date=September 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated